Based on analysts offering 12 month price targets for FATE in the last 3 months. The average price target is $ with a high estimate of $10 and a low. The Fate Therapeutics stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Stock analysis for Fate Therapeutics Inc (FATE:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It i Show More. Compare. EPS. $ All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy. Fate Therapeutics (FATE) has been upgraded to a Zacks Rank #2 (Buy), reflecting.
View the real-time FATE price chart on Robinhood and decide if you want to buy or sell commission-free. Other fees such as trading (non-commission) fees. Research Fate Therapeutics' (Nasdaq:FATE) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance and. FATE | Complete Fate Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Fate Therapeutics Inc. company facts, information and financial ratios from MarketWatch. Based on short-term price targets offered by 15 analysts, the average price target for Fate Therapeutics comes to $ The forecasts range from a low of $ The 42 analysts offering price forecasts for Fate Therapeutics have a median target of , with a high estimate of and a low estimate of Fate Therapeutics Inc FATE:NASDAQ · Open · Day High · Day Low · Prev Close · 52 Week High · 52 Week High Date03/07/24 · 52 Week Low · Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Fate Therapeutics Announces Pricing of $ Million Underwritten Offering and Concurrent Private Placement. SAN DIEGO, March 19, (GLOBE NEWSWIRE) -- Fate. Get the latest Fate Therapeutics Inc (FATE) real-time quote, historical performance, charts, and other financial information to help you make more informed. (NASDAQ: FATE) Fate Therapeutics currently has ,, outstanding shares. With Fate Therapeutics stock trading at $ per share, the total value of Fate.
Fate Therapeutics Inc (FATE) Q4 Earnings Call Transcript. FATE earnings call for the period ending December 31, Motley Fool Transcribers |. Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. View Fate Therapeutics, Inc. FATE stock quote prices, financial information, real-time forecasts, and company news from CNN. FATE - Fate Therapeutics, Inc. Stock - Stock Price, Institutional Ownership, Shareholders (NasdaqGM). The average price target is $ with a high forecast of $ and a low forecast of $ The average price target represents a % change from the last. Fate Therapeutics Inc. ; Market Value, $M ; Shares Outstanding, M ; EPS (TTM), -$ ; P/E Ratio (TTM), N/A ; Dividend Yield, N/A. Discover real-time Fate Therapeutics, Inc. Common Stock (FATE) stock prices, quotes, historical data, news, and Insights for informed trading and investment. View live Fate Therapeutics, Inc. chart to track its stock's price action. Find market predictions, FATE financials and market news. Fate Therapeutics (FATE) has a Smart Score of 8 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund.
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes. Fate Therapeutics Inc. ; Open. $ Previous Close$ ; YTD Change. %. 12 Month Change. % ; Day Range · 52 Wk Range - Fate Therapeutics (FATE) reported Q2 earnings per share (EPS) of -$, beating estimates of -$ by %. In the same quarter last year, Fate. PRO. Tomorrow's Action in Apple Will Be Important and the Stock Must Hold Over $ Failure to hold over that line will have me exiting for fear that all we. (NASDAQ:FATE) Shares Bought by Citigroup Inc., The institutional investor owned 1,, shares of the biopharmaceutical company's stock after purchasing an.
Is FATE Therapeutics a buy!? 🔻 FATE stock PLUMMETS 61% after layoffs announcement
The average one-year price target for Fate Therapeutics, Inc. is $ The forecasts range from a low of $ to a high of $ A stock's price target is.